Endocrinology Drugs Market Share, Growth, Opportunities 2031

Segments - Endocrinology Drugs Market by Products (Hormone, Diabetes, Hypothyroidism, Hypogonadism, and Acromegaly) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Endocrinology Drugs Market Outlook 2031

The Global Endocrinology drugs market size was valued at USD 36.55 Billion in 2022 and is likely reach to USD 69.49 Billion by 2031, expanding at a CAGR of 7.4% during the forecast period, 2023–2031. The growth of the market is attributed to growing prevalence of endocrine diseases.

Growing geriatric population which is more vulnerable to suffer from such diseases owing to hormonal variations is estimated to fuel the market. Endocrinology drugs are used to treat complexities of the endocrine system and modulate the hormonal changes in the body.

They are specifically focused towards pituitary, endocrine organs, adrenals, thyroid, testes, ovaries, and pancreas that regulate hormone secretions.

Unhealthy lifestyle such as work stress, huge intake of cholesterol, and weight gain, eventually leads to inception of new drug delivery systems, malfunctioning of the system, and increasing disposable income which is expected to propel the market.

The adoption rate of formulations of existing drugs and novel dosage forms is expected to increase as the number of patients for the treatment of such disorders.

Market Trends, Drivers, Restraints, and Opportunities

Rising prevalence of endocrine diseases are expected to drive endocrinology drugs market
Rising geriatric population which is more vulnerable to suffer from such diseases, which is expected to boost the market.
Unhealthy lifestyle such as work stress, high intake of cholesterol, and weight gain is expected to be a key factor to accelerate the market.
Extensive research & development activities, inception of new drug delivery systems, and rising disposable income are expected to propel the market.
Increasing adoption of formulations of existing drugs and novel dosage forms are the key drivers of the market in the coming years.
Illegal use of drugs for better performance by sports professionals is expected to restrain the market growth.

Scope of Endocrinology Drugs Market Report

The report on the global endocrinology drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Endocrinology Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Products (Hormone, Diabetes, Hypothyroidism, Hypogonadism, and Acromegaly)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	F. Hoffmann-La Roche AG.; Alacer Corporation; Pfizer Inc.; Abbott Laboratories; Novartis International AG; Eli Lilly and Company; Facet Biotech Corporation; Novo Nordisk A/S, and Sanofi.

Endocrinology Drugs Market Segment Insights

The diabetes segment is expected to grow at a rapid pace

Based on products, the global endocrinology drugs market is segregated into hormone, diabetes, hypothyroidism, hypogonadism, and acromegaly. The diabetes segment accounts for a key share of the market owing to the presence of strong product pipelines and novel drug therapies.

Meanwhile, the hypogonadism segment is anticipated to expand at a rapid pace during the forecast period due to increasing prevalence of deficiency of testosterone and associated complications.

Endocrinology Drugs Market Regional Outlook

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America accounts for a key share of the market owing to rising prevalence of endocrine diseases and increasing adoption of hormone replacement therapies.

The market of Asia Pacific is estimated to expand at a rapid pace during the forecast period due to increasing R&D activities and growing healthcare infrastructure.

Segments

Products

Hormone
Diabetes
Hypothyroidism
Hypogonadism
Acromegaly

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

F. Hoffmann-La Roche AG.
Alacer Corporation
Pfizer Inc.
Abbott Laboratories
Novartis International AG
Eli Lilly and Company
Facet Biotech Corporation
Novo Nordisk A/S
Sanofi

Competitive Landscape

Key players competing in the endocrinology drugs market include F. Hoffmann-La Roche AG.; Alacer Corporation; Pfizer Inc.; Abbott Laboratories; Novartis International AG; Eli Lilly and Company; Facet Biotech Corporation; Novo Nordisk A/S, and Sanofi.

Some of these players are using several market strategies such as acquisitions, merger, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares and to generate revenue and raise their production line of the business in the coming years.

Endocrinology Drugs Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Endocrinology Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Endocrinology Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Endocrinology Drugs Market - Supply Chain
  4.5. Global Endocrinology Drugs Market Forecast
     4.5.1. Endocrinology Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Endocrinology Drugs Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Endocrinology Drugs Market Absolute $ Opportunity
5. Global Endocrinology Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Endocrinology Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Endocrinology Drugs Demand Share Forecast, 2019-2026
6. North America Endocrinology Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Endocrinology Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Endocrinology Drugs Demand Share Forecast, 2019-2026
7. Latin America Endocrinology Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Endocrinology Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Endocrinology Drugs Demand Share Forecast, 2019-2026
8. Europe Endocrinology Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Endocrinology Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Endocrinology Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Endocrinology Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Endocrinology Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Endocrinology Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Endocrinology Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Endocrinology Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Endocrinology Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Endocrinology Drugs Market: Market Share Analysis
  11.2. Endocrinology Drugs Distributors and Customers
  11.3. Endocrinology Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. F. Hoffmann-La Roche AG.
     11.4.2. Alacer Corporation
     11.4.3. Pfizer Inc.
     11.4.4. Abbott Laboratories
     11.4.5. Novartis International AG
     11.4.6. Eli Lilly and Company
     11.4.7. Facet Biotech Corporation